Abstract：Objective To investigate the clinical effect of Docetaxel and Lobaplatin combined with radiotherapy in the treatment of middle late stage esophageal cancer.Methods Eighty patients with middle late stage esophageal cancer admitted to our hospital from January to December 2015 were selected as the research objects,they were divided into control group and observation group according to different treatment methods,with 40 cases in each group.Patients in the control group were given radiotherapy only,while patients in the observation group were given Docetaxel+Lobaplatin+radiotherapy,the total effective rate of clinical treatment,the total incidence of complications and the survival rate of 1,2 and 3 years were compared between the two groups.Results The total effective rate of the observation group was significantly higher than that of the control group,the difference was significant(P＜0.05).There was no significant difference in the total incidence of complications between the two groups(P＞0.05).The 1,2 and 3 years survival rates of the patients in the observation group were 80.00%,65.00%and 50.00%respectively,which were significantly higher than 57.50%,42.50%and 27.50%,respectively in the control group,the differences were significant(P＜0.05).Conclusion Docetaxel and Lobaplatin combined with radiotherapy can improve the clinical efficacy and survival rate of patients with middle late stage esophageal cancer,which is worthy of clinical promotion.
郭峰. 多西他赛加洛铂联合放疗治疗中晚期食管癌患者的临床效果[J]. 中国当代医药, 2019, 26(8): 74-76.
GUO Feng. Clinical effect of Docetaxel and Lobaplatin combined with radiotherapy in the treatment of middle late stage esophageal cancer. 中国当代医药, 2019, 26(8): 74-76.
京公网安备 11010502046607号